Related by context. All words. (Click for frequent words.) 72 Phase III LibiGel 68 Phase Ia 67 Phase IIIb clinical 67 ongoing Phase IIIb 67 Phase Ib II 67 LibiGel ® testosterone gel 67 Phase #b/#a 67 phase IIb clinical 66 phase Ib 66 Phase III pivotal 66 Phase Ib 66 forodesine 66 malignant mesothelioma Alfacell 66 viral kinetic 66 APEX PD 66 blinded randomized placebo controlled 66 Phase 1b trial 66 LibiGel ® 66 RSD# oral 66 PROPEL trial 66 dose escalation phase 66 Phase III Pivotal 66 COSIRA trial 65 oral ridaforolimus 65 alvespimycin 65 SUCCEED trial 65 Pivotal Phase III 65 Phase 2b clinical 65 phase IIb 65 MAGE A3 ASCI 65 LibiGel testosterone gel 65 enzastaurin 65 Zemplar Capsules 65 GetGoal Phase III 65 bevirimat Study 65 MERLIN TIMI 65 registrational trial 65 phase IIb trial 65 CHAMPION PCI 65 Phase 1b clinical trials 65 Phase Ib clinical 65 placebo controlled clinical 65 REVIVE Diabetes 65 pharmacokinetic PK study 65 tesmilifene 65 LUMINATE 65 multicenter Phase 64 TOCOSOL Paclitaxel 64 neratinib 64 Tanespimycin 64 Phase #b/#a clinical 64 rALLy clinical trial 64 DSMB 64 Phase 1a clinical 64 Board DSMB 64 BioSante LibiGel Phase III 64 EOquin TM 64 SPIRIT FIRST 64 phase IIIb 64 preclinical efficacy 64 randomized Phase 2b 64 Phase IIa trials 64 Phase 2a clinical 64 OPT CHF 64 Phase III psoriasis 64 multicenter Phase III 64 phase IIa 64 Proellex TM 64 BioNumerik 64 Phase 1b 64 midstage clinical 64 Androxal TM 64 INSPIRE Trial Phase III 64 European Sepsis Trial 64 velafermin 64 XL# XL# XL# XL# 64 Phase Ib study 64 phase IIa clinical 64 LibiGel 63 MEND CABG II 63 Dacogen injection 63 confirmatory Phase 3 63 Phase 2a trial 63 XL# SAR# 63 Phase III Clinical Trial 63 FOLOTYN ® 63 Phase III metastatic melanoma 63 ENDEAVOR IV 63 randomized Phase IIb 63 clinical pharmacology studies 63 Anturol TM 63 Phase Ib clinical trials 63 MGN# 63 CRMD# 63 pivotal Phase III 63 Multiple Ascending Dose 63 BLOOM Behavioral modification 63 Capesaris 63 Phase IIB 63 ThermoDox ® clinical 63 ataluren 63 lintuzumab 63 Allovectin 7 ® 63 Cloretazine 63 lorcaserin Phase 63 confirmatory clinical 63 budesonide foam 63 STRIDE PD 63 Phase IIIb 63 ThermoDox R 63 NEBIDO 63 CoFactor 63 PSMA ADC 63 Phase 2b study 63 Virulizin ® 63 MEND CABG 63 EFAPROXYN 63 bepotastine besilate nasal spray 63 INCB# [001] 62 rNAPc2 62 rALLy trial 62 Bezielle 62 EXPLORE Xa 62 unique alkylating agent 62 BLA filing 62 Phase IIa trial 62 tramiprosate Alzhemed TM 62 CURE AF 62 YONDELIS 62 ABSORB trial 62 Exelixis compounds 62 confirmatory Phase III 62 placebo controlled Phase 62 Aflibercept 62 GENASIS trial 62 confirmatory pivotal 62 NO# [002] 62 Phase Ib IIa 62 Phase III 62 Amrubicin 62 DSMB recommended 62 successfully commercialize Iluvien 62 tolerability profiles 62 opioid induced bowel dysfunction 62 pain palliation 62 evaluating mipomersen 62 APTIVUS 62 OvaRex R 62 lesinurad 62 Phase III clinical 62 LibiGel BioSante 62 NP2 Enkephalin 62 Zenvia ™ 62 bazedoxifene 62 pharmacokinetic PK 62 CRLX# 62 SILENOR 62 BRIM3 62 aflibercept 62 pivotal bioequivalence 62 CALGB 62 Fibrillex TM 62 oral deforolimus 62 LEVADEX ™ 62 Ophena TM 62 dosing cohort 62 IMC #B 62 budesonide MMX Phase III 62 BRIM2 62 axitinib 62 ADVANCE PD 62 R#/MEM # 62 PRTX 62 CTA# Injection 62 Plenaxis TM 62 EURIDIS 62 SYMMETRY trial 62 phase IIb study 62 thorough QT 62 Empatic ™ 62 UVIDEM 62 ularitide 62 Phase III multicenter 62 PANVAC VF 62 dose escalation Phase 62 placebo controlled Phase III 62 unblinded 62 CALGB # [002] 62 Randomized Phase II 62 Archexin 62 CYT# potent vascular disrupting 62 dose escalation clinical 62 randomized controlled multicenter 62 metastatic HRPC 62 Prostate Lung Colorectal 62 EchoCRT 62 PRESEPT 62 ELACYT 62 EDEMA3 62 metastatic pancreatic 62 PRECISE trial 62 interferon gamma 1b 62 TOLAMBA 62 Pivotal Trial 62 Advaxis Phase 62 CIP ISOTRETINOIN 62 relapsed MM 62 OvaRex ® MAb 62 RE SURGE 62 BrachySil 62 Exelixis XL# 62 Phase III ADT 62 phase 2a 62 Ocrelizumab 61 MGd 61 Truvada tablets 61 farletuzumab 61 EmbraceAC 61 BCIRG 61 Stedivaze 61 pharmacokinetics PK 61 glufosfamide 61 GLP toxicology studies 61 mertansine 61 Urocortin 2 61 evaluating Actimmune 61 ALN VSP Phase 61 Asentar 61 PHX# 61 multiple ascending dose 61 BR.# 61 ENDEAVOR III 61 Panzem R NCD 61 MEK Inhibitor 61 Allovectin 7 61 Phase 2b Clinical Trial 61 recurrent metastatic ovarian cancer 61 vidofludimus 61 urocortin 2 61 Phase III placebo controlled 61 Phase 2b trial 61 cangrelor 61 Phase IIb III 61 recurrent glioma 61 evaluating tivozanib 61 LUX Lung 61 HCV SPRINT 61 faropenem 61 APPRAISE 61 LAB CGRP 61 Tarceva TM 61 ENRICH trial 61 elotuzumab 61 lead Aganocide compound 61 azilsartan medoxomil 61 CR# vcMMAE 61 AVADO 61 Ixempra 61 ToGA 61 CONQUER OB 61 multicenter placebo controlled 61 TACI Ig 61 Tectin TM 61 EMPHASIS HF trial 61 CLIRS 61 Cloretazine ® 61 AEG# 61 ospemifene 61 EOquin 61 eprotirome 61 ISTODAX 61 Ozarelix 61 MEK inhibitor RDEA# 61 granted Ortec 61 TG MV 61 Zerenex 61 Duromist ™ 61 PEG SN# 61 Afatinib 61 Prostate AdenoCarcinoma Treatment 61 Testosterone MDTS ® 61 PRECISE Trial 61 phase Ib clinical 61 Virulizin R 61 Glufosfamide 61 ganetespib 61 Telik logo TELINTRA 61 QLT# 61 hemostatic efficacy 61 GATTEX ® 61 Onrigin 61 galiximab 61 Phase 2b kidney transplant 61 ZYBRESTAT fosbretabulin 61 TBC# 61 Combination REOLYSIN R 61 GAMMAGARD 61 registrational 61 aplindore 61 Aurexis 61 PrevOnco ™ 61 Phase 2b clinical trials 61 Prestara TM 61 Thorough QT 61 PXD# 61 CEQ# 61 ABSORB clinical 61 Ophena 61 ENESTnd 61 oral picoplatin 61 PORxin TM platforms 61 serum phosphorous 61 Bayer HealthCare Onyx Pharmaceuticals 61 KRN# 61 vernakalant oral 61 AIR CF1 61 cancer indications bafetinib 61 GATTEX TM 61 GVAX 61 solid tumors ZYBRESTAT 61 oral calcitonin 61 Prestara 61 pharmacokinetics pharmacodynamics 60 TRISENOX 60 dose escalation trial 60 riociguat 60 AVOREN 60 Panzem R 60 mg kg BID 60 Clonicel 60 Phase 1a 60 Phase III ThermoDox 60 Luveniq 60 registrational Phase 60 ZACTIMA 60 oral prodrug 60 ISIS # 60 Oracea TM 60 Aryplase 60 Neuradiab 60 octreotide implant 60 DASISION 60 intravenous RSD# 60 MIST II 60 Xanafide 60 ONTARGET 60 BLA submission 60 HuMax EGFr 60 Nasdaq PGNX today 60 multicenter prospective 60 APEX AMI trial 60 QNEXA 60 AQUAVAN R 60 Dose escalation 60 PEARL SC 60 TAXUS VI 60 lomitapide 60 CIMZIA ™ 60 placebo controlled clinical trials 60 CUSTOM III 60 LEUKINE 60 Phase III HEAT 60 INTEGRILIN R eptifibatide Injection 60 Teriflunomide 60 dalbavancin 60 pharmacokinetic pharmacodynamic 60 trastuzumab DM1 T DM1 60 CAMMS# 60 CLARITY study 60 bazedoxifene conjugated estrogens 60 OMAPRO ™ 60 dosing cohorts 60 KNS # 60 induced macular edema 60 blinded placebo controlled 60 zileuton IV 60 TELCYTA 60 MIVI TRUST 60 Sapacitabine 60 Phase 1b clinical 60 AIM HIGH 60 Trial PCPT 60 multicenter randomized clinical 60 ATACAND 60 Efficacy Results 60 R roscovitine 60 PREOS R 60 Phase 2a 60 Onrigin TM 60 lintuzumab SGN 60 pharmacodynamic PD 60 IIa trial 60 recombinant PSMA vaccine 60 Multicenter Automatic Defibrillator Implantation 60 COU AA 60 oral rivaroxaban 60 multicenter clinical 60 Forodesine HCl 60 Phase IIb trial 60 ASCEND HF 60 mapatumumab 60 Folfox 60 Deforolimus 60 evaluating T DM1 60 REVIVE TA 60 pertuzumab 60 GOUT 60 HGS ETR1 60 ongoing Phase 1b 60 Crofelemer budesonide foam 60 CCR5 mAb 60 CHARM Added 60 vosaroxin 60 alvimopan 60 Heplisav 60 double blinded placebo 60 Surfaxin LS 60 sunitinib malate 60 HORIZONS AMI trial 60 MOZOBIL 60 Hedgehog Pathway Inhibitor 60 EVIZON TM squalamine lactate 60 PRIMO CABG2 60 preclinical pharmacokinetic 60 Phase III Clinical Trials 60 Phenoptin 60 PLK1 SNALP 60 ACTIVE W 60 ExCell study 60 bicifadine 60 Completes Patient Enrollment 60 Perforomist ™ Inhalation Solution 60 Omigard 60 Æterna Zentaris 60 Degarelix 60 RELOVAIR ™ 60 EDEMA3 trial 60 CLIRS trial 60 pharmacodynamic profiles 60 dirucotide MBP# 60 ATL# [001] 60 inhaled AAT 60 velafermin belinostat 60 deforolimus 60 SPIRIVA HandiHaler 60 multicenter Phase II 60 midstage trials 60 Phase #/#a 60 asthma immunotherapeutic 60 EMPOWER ™ 60 Georges Gemayel 60 teduglutide 60 XL# anticancer compounds 60 huC# DM4 60 XL# XL# XL# 60 includes TOLAMBA TM 60 Hsp# Inhibitor 60 Exherin TM 60 eprodisate Fibrillex TM 60 THALOMID 60 Pivotal Clinical Trial 60 Phase IIb trials 60 TRA 2P 60 phase III isavuconazole 60 desvenlafaxine succinate 60 HCV NS5B polymerase 60 SILENOR TM 60 CTAP# Capsules 60 IV APAP 60 ACAPODENE 60 Triolex 60 Second Pivotal Phase 60 Primary endpoints 60 Prostate Cancer Prevention 60 SUPPRELIN R LA 59 Ovarian PLCO Cancer 59 IMPACT DCM trial 59 Allovectin 7 R 59 elacytarabine 59 LUVENIQ 59 Committee IDMC 59 placebo controlled randomized 59 PROVENGE ® 59 ponatinib 59 RSD# 59 IMPACT IMmunotherapy 59 GRN# 59 CCX# 59 Phase lll 59 Myocet 59 patients evaluable 59 PLCO 59 candidate CRLX# 59 ENDEAVOR II 59 ALN VSP 59 Sym# 59 SinuNase TM 59 Phase 2a clinical trials 59 FDA Approvable Letter 59 senicapoc 59 Azedra 59 oral talactoferrin 59 NASDAQ BPAX 59 IMA# 59 ExTRACT TIMI 59 dose escalation 59 selective androgen receptor modulator 59 elagolix 59 squalamine 59 enoximone 59 relapsed refractory multiple myeloma 59 CONBRIZA 59 talactoferrin 59 ORBIT II 59 Tyrima 59 Triapine R 59 mg/m2 cohort 59 pharmacodynamic effects 59 apricitabine ATC 59 Phase IIb clinical trials 59 Cloretazine R VNP#M 59 Alzhemed TM 59 refractory CLL 59 GVAX Pancreas Vaccine 59 ACTEMRA TM 59 treatment naïve genotype 59 LymphoStat B belimumab 59 DAPT Study 59 SNT MC# 59 II Clinical Trial 59 tezampanel NGX# 59 active comparator 59 crizotinib PF # 59 BEXXAR 59 Ganite ® 59 AEGR 59 assessing T DM1 59 fosbretabulin 59 Corlux 59 pralatrexate injection folate analogue 59 refractory metastatic 59 CRx 59 HDL Selective Delipidation 59 EVIZON TM 59 CAPACITY trials 59 StemEx R 59 ChronVac C R 59 Dr. Yatscoff 59 tremelimumab 59 atacicept 59 EQUIP OB 59 NEUVENGE 59 TASKi2 59 Trubion Pharma 59 Phase IIb Clinical Trial 59 evaluating satraplatin 59 IMPACT DCM clinical 59 Pivotal Phase 59 sorafenib tablets 59 evaluating REVLIMID 59 Dextofisopam 59 catheter occlusion 59 BCX# 59 RGB # 59 Motesanib 59 Initiated Phase 59 oral methylnaltrexone 59 PROSTVAC VF 59 relapsed myeloma 59 Phase IIIb study 59 Randomized controlled 59 treatment naive genotype 59 delivers fluocinolone acetonide FA 59 AVN# Phase 59 Regeneron Pharma 59 GRAVITAS trial 59 Dose Limiting Toxicity DLT 59 website http:/www.celsion.com 59 Novolimus 59 NVA# 59 Meets Primary Endpoint 59 Canvaxin 59 trastuzumab emtansine T DM1 59 MADIT II 59 BENICAR HCT 59 oral FTY# 59 OMNARIS HFA 59 Phase IIa clinical trials 59 AVERROES 59 Cariprazine 59 REGEN trial 59 favorable pharmacokinetic profile 59 SPIRIT IV 59 APTIVUS r 59 Icatibant 59 Delcath Phase III 59 FOLOTYN 59 dacetuzumab 59 MAXY alpha 59 Zevalin consolidation 59 PS# [001] 59 ALSYMPCA 59 LymphoStat B Phase 59 Mylotarg 59 CINQUIL 59 acyclovir Lauriad R 59 randomized discontinuation trial 59 Charles Dullin School 59 TKB# 59 AZX# Phase 59 R sorafenib tablets 59 including eniluracil ADH 59 class mGluR5 inhibitor 59 Budesonide foam crofelemer 59 ONCONASE R 59 Zenvia Phase III 59 First Patient Enrolled 59 clevidipine 59 abiraterone acetate 59 dextofisopam 59 RhuDex R 59 PDX pralatrexate 59 Octreolin 59 Raptiva ® 59 arzoxifene 59 Sulonex TM 59 urate lowering 59 HCD# [002] 59 PEGINTRON TM 59 TEC #OL 59 Cellegesic 59 RE LY ® 59 compound INCB# 59 lucinactant 59 metastatic castration resistant 59 ZOLINZA 59 VITAL Trial 59 VICTOR E1 59 Phase #b/#a trial 59 adjuvant GIST 59 placebo controlled multicenter 59 paclitaxel poliglumex 59 dirucotide 59 IMC A# 59 initiated Phase 1b 59 PREGNANT Study 59 Zoraxel 59 R# #mg BID 59 RE LY 59 Bronchitol 59 SIMPADICO 59 Phase IIb clinical 59 Auxilium Pharma 59 ascending dose 59 APEX AMI 59 IMPACT DCM 59 AzaSite TM 59 Traficet EN 59 ROCKET AF 59 Hyphanox 59 antibody MAb 59 Vion Pharmaceuticals 59 GATTEX ™ 59 Plicera 59 Pafuramidine 59 Medidur FA 59 phase III ACCLAIM 59 masked placebo controlled 59 standard chemotherapy regimen 59 tanespimycin 59 PRESEPT study 59 Elocalcitol 59 maximally tolerated dose 59 CIMZIA TM certolizumab pegol 59 By JENNIFER LEARN 59 indibulin 59 TYKERB 59 novel VDA molecule 59 Phase III confirmatory 58 FOLFOX6 chemotherapy regimen 58 teriflunomide 58 Matrix Phase 2b 58 Phase 2a Clinical Trial 58 MAA submission 58 opioid bowel dysfunction 58 See CLINICAL PHARMACOLOGY 58 Robert Motzer MD 58 Dose Ranging Study 58 Long Term Efficacy 58 brivaracetam 58 developing ACAPODENE 58 Golimumab 58 LymphoStat B TM 58 tolerated dose MTD 58 Screening Trial 58 telomerase therapeutic 58 AAG geldanamycin analog 58 cobiprostone 58 OvaRex 58 goserelin 58 ELND# 58 EVEREST II 58 mipomersen 58 dose cohorts 58 Hepatocellular Carcinoma HCC 58 RhuDex 58 Oral Calcitonin 58 PEG PAL 58 CIMZIA R 58 subcutaneous PRO 58 GRNVAC1 58 single ascending dose 58 ancrod 58 REVLIMID lenalidomide 58 LymphoStat B 58 trastuzumab DM1 58 personalized cellular immunotherapy 58 placebo controlled studies 58 Randomized Phase 58 fund BioSante LibiGel 58 Hypertensive adverse reactions 58 Pimavanserin 58 oxymorphone ER 58 regorafenib 58 HGS# 58 CERVARIX 58 NATRECOR R 58 Elagolix 58 relapsed MCL 58 Tezampanel 58 PARTNER Trial 58 tezampanel 58 EXPAREL ™ 58 CCR9 antagonist 58 clinical trial 58 HORIZONS AMI 58 evaluable subjects 58 AQ4N 58 IIa clinical 58 Topline Results 58 dose cohort 58 MORAb 58 CARE HF 58 eniluracil 58 severe hypercholesterolemia 58 HCV RESPOND 2 58 pharmacogenomic translational research 58 sapacitabine CYC# 58 Trofex 58 StemEx 58 Phase IIb 58 GERD migraine headaches 58 TAXUS Element Stent System 58 ACCORD Lipid 58 Fx #A 58 sapacitabine 58 Lovaxin C 58 Val HeFT 58 Phase III randomized controlled 58 Selective Electrochemical Tumor Ablation 58 metastatic GIST 58 MYTHOS trial 58 leading oral taxane 58 blinded randomized 58 tizanidine hydrochloride short 58 liprotamase 58 NATRECOR ® 58 Medidur TM FA 58 incyclinide 58 Pemetrexed 58 Randomized Double blind 58 desvenlafaxine 58 Targretin capsules 58 pharmacokinetic characteristics 58 Testosterone MDTS R 58 Prospective Randomized 58 Initiate Phase 58 prelicensure 58 Arno Therapeutics 58 Entereg R 58 CIMZIA TM 58 Sorafenib HCC Assessment 58 vismodegib 58 JAK inhibitor 58 Lenocta 58 GALNS 58 multicenter randomized placebo controlled 58 PERSEUS clinical program 58 Vandetanib 58 GVAX ® 58 Lung Rx 58 Mr. Bentsur 58 PREZISTA r 58 dependent kinase inhibitor 58 PF # [002] 58 tolerability pharmacokinetics 58 Oxypurinol 58 PRE SURGE 58 NDA Submission 58 utmost importance Breithaupt 58 ozarelix 58 Tesmilifene 58 GSK# [001] 58 Screening Trial DMIST 58 Protexia ® 58 abstracts summarizing 58 dexanabinol 58 Phase IIb kidney transplant 58 Androxal 58 KYNAPID 58 Inhalation Solution 58 seliciclib CYC# 58 nonclinical studies 58 Urocidin 58 secondary efficacy endpoints 58 SinuNase ™ 58 HER2 positive metastatic breast 58 systemic Phase 1b 58 Canvaxin TM 58 intravesical infusion therapy 58 albiglutide 58 aflibercept VEGF Trap 58 rALLy 58 ORENCIA R 58 ACOSOG Z# 58 Daclizumab 58 vernakalant hydrochloride 58 blind multicenter 58 EOquin TM phase 58 Multicenter Phase 58 ARCOXIA 58 MVax 58 davunetide intranasal AL 58 Rexahn Pharmaceuticals 58 randomized Phase III 58 Xeloda ® 58 EVIZON 58 AIR2 Trial 58 CHAMPION PLATFORM 58 Phase 2b 58 investigational monoclonal antibody 58 tecarfarin 58 TRO# 58 CLL8 58 Viprinex TM 58 HPTN 58 PROSTVAC ® 58 Initiate Phase II 58 initiated Phase Ib 58 Genasense ® oblimersen 58 Arimoclomol 58 ARRY # 58 worsening thrombocytopenia 58 evaluating carfilzomib 58 Genasense ® 58 LUNESTA TM 58 pharmacokinetic studies 58 Initiates Phase III 58 prospectively defined 58 randomized controlled Phase 58 Xelox 58 Fibrin Pad 58 BST CarGel R 58 immatics 58 prospective randomized multicenter 58 QuatRx 58 initiate multicenter 58 SUTENT 58 HOPE TOO 58 lexidronam injection 58 TIMI Study Group 58 Personalized Immunotherapy 58 ostarine 58 OncoVEX GM CSF 58 anticoagulant reversing agent 58 multicenter randomized Phase III 58 PROMACTA 58 Saforis 58 CD# CEA 58 ACCEDE 58 PEG INTRON R 58 Tolvaptan 58 PSN# [002] 58 BIM #A# 58 EndoTAG TM -1 58 Phase IIb Trial 58 please visit http:/www.atherogenics.com 58 STELARA 58 PreCISe study 58 Trizytek 58 PDE4 inhibitor 58 HQK 58 double blinded randomized 58 Thalomid ® 58 eritoran 58 AZILECT R 58 BEXXAR Therapeutic Regimen 58 Corautus 58 gadobutrol 58 Phase 1b dose escalation 58 randomized controlled clinical trials 58 TPI ASM8 58 Bicifadine 58 Cetrorelix 58 PRoFESS 58 Aztreonam lysine 58 metastatic colorectal 58 YOUR LOCAL ANIMAL SHELTER 58 DEB# 58 ALTU 58 Celsion Corporation 57 PFO migraine 57 Syncria 57 IL# PE#QQR 57 CA4P 57 Fast Track Status 57 hypoxia activated prodrug 57 canakinumab 57 Tavocept 57 initiate Phase IIb 57 Neuradiab TM 57 Patient Accrual 57 RenalGuard System TM 57 Fortical R 57 non nucleoside HCV 57 dimebon 57 #D#C# 57 QTinno 57 Phase 2b Trial 57 PREOS 57 Serdolect ® 57 Sulonex 57 Ziopharm 57 Cleviprex TM clevidipine 57 AeroLEF TM 57 Ceplene/IL-2 57 ENABLE Phase 2 57 Initiates Phase II 57 HGS ETR2 57 mecarbil 57 ENGAGE AF TIMI 57 unresectable malignant mesothelioma UMM 57 pradefovir 57 HepeX B TM 57 PRX # 57 Pirfenidone 57 TYZEKA 57 CEL SCI Phase III 57 PROTECT AF 57 Triapine 57 RECORD1 57 PhG alpha 1 57 celgosivir 57 Vernakalant 57 SCH # 57 NEUMUNE 57 GENR 57 Opexa 57 Oral NKTR 57 initiate Phase 1b 57 PRIMO CABG 57 bile duct tumor 57 voreloxin 57 Progenta TM 57 TYGACIL 57 zileuton CR 57 Phase IIa clinical 57 QTinno TM 57 REALITY Trial 57 Demonstrates Sustained 57 Seliciclib 57 Randomized Controlled 57 pegloticase 57 Romidepsin 57 motesanib 57 Wisconsin Sleep Cohort 57 kidney urologic 57 Tesetaxel 57 COMFORT II 57 FOSRENOL R 57 Diabetic Macular Edema 57 XIENCE V Stent System 57 product platforms AZX# 57 Acetavance 57 LibiGel ® Phase III 57 DAVANAT 57 Simulect 57 AZX# 57 Maximum Tolerated Dose MTD 57 cinacalcet HCl 57 Curaxin CBLC# 57 #/#/# Cytokinetics Incorporated 57 ocrelizumab 57 randomized discontinuation 57 R#/MEM 57 Aplidin 57 avanafil PDE5 inhibitor 57 Phase III trials 57 DermaVir Patch